《LANCET,4月1日,Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?》

  • 来源专题:COVID-19科研动态监测
  • 编译者: xuwenwhlib
  • 发布时间:2020-04-02
  • Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?

    Hua Zhao ,Dingding Shen ,Haiyan Zhou ,Jun Liu,Sheng Chen

    Published:April 01, 2020DOI:https://doi.org/10.1016/S1474-4422(20)30109-5

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), originating from Wuhan, is spreading around the world and the outbreak continues to escalate. Patients with coronavirus disease 2019 (COVID-19) typically present with fever and respiratory illness.1 However, little information is available on the neurological manifestations of COVID-19. Here, we report the first case of COVID-19 initially presenting with acute Guillain-Barré syndrome.

    On Jan 23, 2020, a woman aged 61 years presented with acute weakness in both legs and severe fatigue, progressing within 1 day. She returned from Wuhan on Jan 19, but denied fever, cough, chest pain, or diarrhoea. Her body temperature was 36·5°C, oxygen saturation was 99% on room air, and respiratory rate was 16 breaths per min. Lung auscultation showed no abnormalities. Neurological examination disclosed symmetric weakness (Medical Research Council grade 4/5) and areflexia in both legs and feet. 3 days after admission, her symptoms progressed. Muscle strength was grade 4/5 in both arms and hands and 3/5 in both legs and feet. Sensation to light touch and pinprick was decreased distally.

  • 原文来源:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30109-5/fulltext
相关报告
  • 《LANCET,3月17日,Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-18
    • Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis Yong Xiao Hong Pan Qian She Fen Wang Mingkai Chen Published:March 17, 2020DOI:https://doi.org/10.1016/S2468-1253(20)30080-7 We read the Comment by Chao Zhang and colleagues1 in The Lancet Gastroenterology & Hepatology on liver injury in coronavirus disease 2019 (COVID-19) with great interest. Given that patients with decompensated cirrhosis have a higher risk of, and mortality from, infection, preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in this patient population is a challenging task.2 We provide our experience of COVID-19 prevention in patients with decompensated cirrhosis in Wuhan, China.
  • 《LANCET,4月3日,Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-04-04
    • Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? David M G Halpin,Rosa Faner,Oriol Sibila,Joan Ramon Badia,Alvar Agusti Published:April 03, 2020DOI:https://doi.org/10.1016/S2213-2600(20)30167-3 Coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an acute respiratory disease that can lead to respiratory failure and death.1 Previous epidemics of novel coronavirus diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), were associated with similar clinical features and outcomes.2 One might anticipate that patients with chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD) and asthma, would be at increased risk of SARS-CoV-2 infection and more severe presentations of COVID-19. However, it is striking that both diseases appear to be under-represented in the comorbidities reported for patients with COVID-19, compared with the global burden of disease estimates of the prevalence of these conditions in the general population (table); a similar pattern was seen with SARS. By contrast, the prevalence of diabetes in patients with COVID-19 or SARS is as high as or higher than the estimated national prevalence, as might be expected.